Despite the use of 20 mg tamoxifen twice daily, there was no significant improvement in pain, curvature, or plaque size when compared to placebo (19)
2000 Sep Nazzareno Ballatori, Suzanne M Krance, Sylvia Notenboom, Shujie Shi, Kim Tieu, Christine L Hammond
Clinical results have shown notable improvements in liver indicators and a reduction in insulin resistance
Early studies suggest retatrutide may cause more weight loss than semaglutide and tirzepatide, with some people losing 30% of their body weight or more
All treatments were well tolerated, as we did not observe any significant weight loss (Extended Data Fig
Fatigue and constipation also peak during early treatment before your gastrointestinal tract adapts to the medication's mechanism